|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1996-12-17
|
|
pubmed:abstractText |
We have developed a quantitative reverse transcriptase-polymerase chain reaction method for the quantitation of AML1-MTG8 transcripts in patients with AML-M2 and t(8;21) in different phases of the disease. Using this method, we have tested sequential samples from 13 patients to monitor minimal residual disease and were able to show a significant increase in AML1-MTG8 transcripts level in two patients 2 and 4 months before clinical relapse. In five patients tested at presentation and then sequentially at remission, we detected a marked decrease in the level of AML1-MTG8 transcripts as the treatment progressed. Patients in long-term remission of their disease had a level of up to 1 x 10(3) AML1-MTG8 molecules/microgram RNA. Two patients tested 2 and 4 months before hematologic relapse showed a level of 0.71 x 10(5) molecules/microgram RNA and this level increased further during relapse to 0.71 x 10(7) and 2.27 x 10(5) molecules/microgram RNA, respectively. Our results show that quantitation of AML1-MTG8 transcripts by competitive polymerase chain reaction is valuable in predicting early relapse in AML with t(8;21). Identification of at-risk patients may allow treatment to be modified to include additional or alternative therapy such as bone marrow transplantation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Core Binding Factor Alpha 2 Subunit,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Proteins, Fusion,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/RUNX1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/RUNX1T1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3704-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8916934-Adolescent,
pubmed-meshheading:8916934-Adult,
pubmed-meshheading:8916934-Bone Marrow Examination,
pubmed-meshheading:8916934-Chromosomes, Human, Pair 21,
pubmed-meshheading:8916934-Chromosomes, Human, Pair 8,
pubmed-meshheading:8916934-Core Binding Factor Alpha 2 Subunit,
pubmed-meshheading:8916934-DNA-Binding Proteins,
pubmed-meshheading:8916934-Disease-Free Survival,
pubmed-meshheading:8916934-Female,
pubmed-meshheading:8916934-Gene Expression Regulation, Leukemic,
pubmed-meshheading:8916934-Humans,
pubmed-meshheading:8916934-Leukemia, Myeloid, Acute,
pubmed-meshheading:8916934-Male,
pubmed-meshheading:8916934-Middle Aged,
pubmed-meshheading:8916934-Neoplasm, Residual,
pubmed-meshheading:8916934-Oncogene Proteins, Fusion,
pubmed-meshheading:8916934-Polymerase Chain Reaction,
pubmed-meshheading:8916934-Prognosis,
pubmed-meshheading:8916934-Proto-Oncogene Proteins,
pubmed-meshheading:8916934-RNA, Messenger,
pubmed-meshheading:8916934-RNA, Neoplasm,
pubmed-meshheading:8916934-Risk,
pubmed-meshheading:8916934-Sensitivity and Specificity,
pubmed-meshheading:8916934-Transcription Factors,
pubmed-meshheading:8916934-Translocation, Genetic
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21).
|
|
pubmed:affiliation |
University Department of Haematology, Manchester Royal Infirmary, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
